- Home
- SHOT vs UBX Comparison
SHOT vs UBX Comparison
Compare SHOT & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- UBX
- Stock Information
- Founded
- SHOT 2018
- UBX 2009
- Country
- SHOT United States
- UBX United States
- Employees
- SHOT N/A
- UBX N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- SHOT Health Care
- UBX Health Care
- Exchange
- SHOT Nasdaq
- UBX Nasdaq
- Market Cap
- SHOT 30.4M
- UBX 13.8M
- IPO Year
- SHOT 2020
- UBX 2018
- Fundamental
- Price
- SHOT $0.38
- UBX $0.29
- Analyst Decision
- SHOT
- UBX Strong Buy
- Analyst Count
- SHOT 0
- UBX 3
- Target Price
- SHOT N/A
- UBX $4.67
- AVG Volume (30 Days)
- SHOT 5.6M
- UBX 1.6M
- Earning Date
- SHOT 08-13-2025
- UBX 08-05-2025
- Dividend Yield
- SHOT N/A
- UBX N/A
- EPS Growth
- SHOT N/A
- UBX N/A
- EPS
- SHOT N/A
- UBX N/A
- Revenue
- SHOT $573,336.00
- UBX N/A
- Revenue This Year
- SHOT N/A
- UBX N/A
- Revenue Next Year
- SHOT N/A
- UBX N/A
- P/E Ratio
- SHOT N/A
- UBX N/A
- Revenue Growth
- SHOT 69.32
- UBX N/A
- 52 Week Low
- SHOT $0.23
- UBX $0.24
- 52 Week High
- SHOT $1.77
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- SHOT 56.11
- UBX 20.79
- Support Level
- SHOT $0.30
- UBX $0.24
- Resistance Level
- SHOT $0.52
- UBX $0.83
- Average True Range (ATR)
- SHOT 0.06
- UBX 0.09
- MACD
- SHOT 0.02
- UBX -0.05
- Stochastic Oscillator
- SHOT 47.37
- UBX 8.46
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.